ATRA Historical PE Ratio Notes

— Atara Biotherapeutics (ticker symbol: ATRA) is a clinical-stage biotechnology company focused on developing off-the-shelf, allogeneic T-cell immunotherapies for patients with serious diseases, including cancer & autoimmune disorders. The company's lead product candidate is tabelecleucel (tab-cel®), which targets Epstein-Barr virus-positive (EBV+) post-transplant lymphoproliferative disorder (PTLD), a rare and life-threatening cancer. Atara operates in a high-risk, high-reward sector, where revenues often lag substantial research & development expenses until key products receive regulatory approval and reach the market. This dynamic is crucial when interpreting historical price, earnings, & price-to-earnings (P/E) ratio data: ATRA has frequently reported negative earnings, leading to either undefined or highly volatile P/E ratios in its history. As you review historical charts, remember that for companies like Atara, market valuations often reflect future potential rather than current profits. Thus, swings in the P/E ratio may correspond more to news about clinical milestones, partnerships, & regulatory decisions than to traditional earnings growth, making the metric less stable and less predictive than for mature, profitable firms.

On this page we presented the ATRA Historical PE Ratio information for Atara Biotherapeutics' stock. The average ATRA historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 7.0. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ATRA historical PE based on this TTM earnings result method is 3.2. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ATRA historical PE result, against the recent PE: when this page was posted on 8/4/2026, the most recent closing price for ATRA had been 8.77, and the most recent quarterly earnings result, annualized, was 0.76. Meanwhile, the most recent TTM earnings summed to 3.12. From these numbers, we calculate the recent ATRA PE on 8/4/2026 based on annualized quarterly EPS was 11.5. Based on ATRA's history, that recent PE is elevated relative to the historical average, with the recent PE 64.3% higher than the historical average PE across our data set for Atara Biotherapeutics. Looking at the recent ATRA PE on 8/4/2026 based on TTM EPS, we calculate the ratio at 2.8. Based on ATRA's history, that recent PE is low relative to the historical average, with the recent PE 12.5% lower than the average PE across our Atara Biotherapeutics data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on ATRA or any other given stock, valuation analysis for ATRA can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Atara Biotherapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ATRA. Thanks for visiting, and the next time you need to research ATRA Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.